Gloucester, United Kingdom
Gloucester, United Kingdom

Time filter

Source Type

An additive manufacturing apparatus comprising a build chamber (101) in which an object is built and a flow device (1a, 1b). The flow device (1a, 1b) comprises a body (2) having a Coand surface (11, 12) and a passageway (10) connectable to a pressurised gas source. The passageway (10) has an opening (5, 6) located adjacent to the Coand surface (11, 12) to, in use, direct a jet of gas over the Coand surface (11, 12). A space adjacent the Coand surface is in fluid communication with the build chamber (101) such that gas drawn into and/or propelled from the space causes gas flow through the build chamber (101).


Patent
Renishaw | Date: 2017-01-25

Neurosurgical apparatus is described that comprises a guidance device (40; 100; 150; 200; 250) comprising a guide tube (42; 104; 152; 202) and a neurosurgical instrument (60; 110) for insertion into the guide tube (42; 104; 152; 202). The inner surface (46; 108) of the guide tube (42; 104; 152; 202) is arranged, for example profiled,to at least partially engage the outer surface (72; 120) of the neurosurgical instrument (60; 110) when inserted therein. The guide tube (42; 104; 152; 202) thus guides the neurosurgical instrument (60; 110) along a predefined path through the guide tube (42; 104; 152; 202). At least one of the guidance device (40; 100; 150; 200; 250) and the outer surface of the neurosurgical instrument (60; 110) are configured to provide a fluid return path (50a-50c; 122a-122c) for carrying any fluid displaced from within the guide tube (42;104; 152; 202) during insertion of the neurosurgical instrument (60; 110) into the guide tube (42; 104; 152; 202). A seal may also be provided for sealing the fluid return path (50a-50c; 122a-122c).


Patent
Renishaw | Date: 2017-01-25

This invention concerns a selective solidification apparatus comprising a build chamber (117), a build platform (102) lowerable in the build chamber (117), a wiper (109) for spreading powder material across the build platform (102) to form successive powder layers of a powder bed (104), an energy beam unit (105) for generating an energy beam (118) for consolidating the powder material, a scanner (106) for directing and focussing the energy beam (118) onto each powder layer and a processor (131) for controlling the scanner (106). The processor (106) is arranged to control the scanner (106) to scan the energy beam across the powder bed (104) to consolidate powder material either side of the wiper (109) when the wiper (109) is moving across the powder bed (104) and to scan the energy beam (118) across at least one of the powder layers during two or more strokes of the wiper (109) across the powder bed (104).


Patent
Renishaw and Metrology Software Products Ltd | Date: 2017-07-19

A calibration device (30) for a machine tool is described that includes a base (36) attachable to a machine tool and a calibration artefact (32), such as a sphere of known radius. A deflection mechanism attaches the calibration artefact to the base and allows movement of the calibration artefact (32) relative to the base (36) when an external force is applied to the calibration artefact (32). The deflection mechanism also maintains the calibration artefact (32) in a defined rest position relative to the base (36) in the absence of an applied external force. A sensor (46) is provided for sensing the extent of movement of the calibration artefact (32) relative to the base (36). A method of using the device (30) with a reference tool to accurately determine a position of a calibration artefact (32) is also described.


Patent
Renishaw | Date: 2017-07-19

This invention concerns a method of manufacturing a part comprising selective laser melting of a powder comprising a steel alloy containing, by weight, 16% to 9% chromium and 12.2% to 13.5% nickel, wherein the powder is substantially non-magnetic


A series of nominally identical production workpieces are measured (88) on a workshop coordinate measuring apparatus. They are corrected (90) using correction values generated (84,86) by comparing coordinate values of a reference workpiece measured (82) on the workshop apparatus with corresponding values derived from external measurements (70,74). To reduce the care and skill required, the external measurements are used to determine reference values (76) of a geometric property of a feature of the reference workpiece, rather than coordinate values corresponding directly to those made on the workshop apparatus. Corresponding coordinate values are then generated (80) from knowledge of the perfect form (72, 78) of the feature of the reference workpiece.


A method of treating a CNS disorder. The method comprises providing a water-soluble histone deacetylase inhibitor, and administering the water-soluble histone deactylase inhibitor directly into a brain via convection enhanced delivery.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FOF-13-2016 | Award Amount: 4.04M | Year: 2016

The ENCOMPASS project principally aims to create a fully digital integrated design decision support (IDDS) system to cover the whole manufacturing chain for a laser powder bed fusion (L-PBF) process encompassing all individual processes within in. The ENCOMPASS concept takes a comprehensive view of the L-PBF process chain through synergising and optimising the key stages. The integration at digital level enables numerous synergies between the steps in the process chain and in addition, the steps themselves are being optimised to improve the capability and efficiency of the overall manufacturing chain. ENCOMPASS addresses the three key steps in the process chain: component design, build process, and post-build process steps (post-processing and inspection). The links between these stages are being addressed by the following five interrelations: 1. Between the design process and both the build and post-build processes in terms of manufacturing constraints / considerations to optimise overall component design 2. Between the design process and build process component-specific L-PBF scanning strategies and parameters to optimise processing and reduce downstream processing 3. Between the design process and the build and post-build processes in terms of adding targeted feature quality tracking to the continuous quality monitoring throughout the process chain 4. Between the build and post-build processes by using build specific processing strategies and adaptation based on actual quality monitoring data (for inspection and post-processing) 5. Between all stages and the data management system with the integrated design decision support (IDDS) system By considering the entire AM process chain, rather than the AM machine in isolation, ENCOMPASS will integrate process decision making tools and produce substantial increases in AM productivity, with clear reductions in change over times and re-design, along with increased right-first time, leading to overall reductions in production costs, materials wastage, and over-processing. This will lead to higher economic and environmental sustainability of manufacturing, and re-inforce the EUs position in industrial leadership in laser based AM.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-24-2015 | Award Amount: 8.36M | Year: 2016

Due to an aging population and the spiralling cost of brain disease in Europe and beyond, EDEN2020 aims to develop the gold standard for one-stop diagnosis and minimally invasive treatment in neurosurgery. Supported by a clear business case, it will exploit the unique track record of leading research institutions and key industrial players in the field of surgical robotics to overcome the current technological barriers that stand in the way of real clinical impact. EDEN2020 will provide a step change in the modelling, planning and delivery of diagnostic sensors and therapies to the brain via flexible surgical access, with an initial focus on cancer therapy. It will engineer a family of steerable catheters for chronic disease management that can be robotically deployed and kept in situ for extended periods. The system will feature enhanced autonomy, surgeon cooperation, targeting proficiency and fault tolerance with a suite of technologies that are commensurate to the unique challenges of neurosurgery. Amongst these, the system will be able to sense and perceive intraoperative, continuously deforming, brain anatomy at unmatched accuracy, precision and update rates, and deploy a range of diagnostic optical sensors with the potential to revolutionise todays approach to brain disease management. By modelling and predicting drug diffusion within the brain with unprecedented fidelity, EDEN2020 will contribute to the wider clinical challenge of extending and enhancing the quality of life of cancer patients with the ability to plan therapies around delicate tissue structures and with unparalleled delivery accuracy. EDEN2020 is strengthened by a significant industrial presence, which is embedded within the entire R&D process to enforce best practices and maximise translation and the exploitation of project outputs. As it aspires to impact the state of the art and consolidate the position of European industrial robotics, it will directly support the Europe 2020 Strategy.


The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of intracerebrally administered CDNF protein therapy in patients with Parkinsons disease (PD), using a neurosurgically implanted Drug Delivery System (DDS), which will also be clinically validated in the study. Thus the TreatER project has two independent goals, either of which alone can have significant impact addressing unmet clinical needs in chronic diseases, and advancing innovative European technologies: 1) Proof-of-concept of CDNF protein therapy for disease modification in PD. The patented European innovation CDNF has further potential in other ER stress related indications. 2) Clinical validation of DDS, an already clinically tested approach for accurately targeted intracerebral infusions in PD. The patented European innovation DDS has also significant potential in other indications needing intracerebral infusions. The clinical study builds on extensive preclinical research and related data on CDNF, including completed acute and chronic toxicology studies in non-human primates supporting an excellent safety profile. Further, the clinical study builds on existing clinical experience on DDS and related neurosurgery. Both conventional and novel means for assessing the efficacy of the treatment will be utilized. This requires strong interdisciplinary expertise and knowledge available in the consortium, including: Regulatory expertise in drug and medical device development; neurological and neurosurgical expertise in PD; PET imaging expertise specific to PD; Scientific expertise in novel neurotrophic factors, in specific CDNF; and GMP manufacturing expertise of novel biological drug compounds. Clinical trial applications are currently being submitted in Finland and Sweden, in accordance with previously obtained scientific advice from regulatory authorities in those countries as well as from MHRA (UK) and EMAs ITF.

Loading Renishaw collaborators
Loading Renishaw collaborators